A flood of new health care IT companies has been pouring into the U.S. health care market. The cause of this torrent: the recognition that as market and regulatory forces alter incentives in health care, IT companies will play a powerful role in combating the overemployment and declining productivity that has plagued this industry and in helping providers improve the quality of care.
GlaxoSmithKline (GSK) has for the fourth consecutive time been ranked No 1 among global pharmaceutical companies assessed for their efforts to improve access to medicine in developing countries.
Released on 17th November by the Access to Medicine Foundation, the 2014 Access to Medicine (ATM) Index gives GSK a composite score of 3.3 out of a possible 5, following an in-depth evaluation of company activities in seven areas that are germane to enhancing access to medicine in developing countries.
How do you turn a genetic disorder into a money-making empire? Grumpy Cat has done it, but is it only acceptable because she is a funny looking feline instead of a human?
Last week, the Department of Health and Human Services welcomed its third group of “entrepreneurs-in-residence” — mainly private-sector tech experts and start-up founders who are spending a year advising the agency on its health IT projects.
AstraZeneca became the latest biotechnology company to expand its manufacturing operations in Maryland when the British drugmaker announced plans last month to enlarge a production facility and add 300 workers in Frederick.
Pieris AG has achieved the fourth milestone payment for its lead Anticalin® program with Daiichi Sankyo Company, Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today. This milestone marks in total the sixth milestone achieved for the parties’ two R&D collaborative projects. Specifically, the milestone was the decision by Daiichi Sankyo to initiate a GLP toxicity study in non-human primates. In 2013, Pieris transferred the program to Daiichi Sankyo, which is responsible for further development of the program.
Takeda Pharmaceutical Company Limited (TSE:4502) today announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology. The creation of Takeda Oncology will improve the company’s ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide. Takeda will sustain its long-standing entrepreneurial approach to oncology research and development while expanding its global commercial network and resources as Takeda Oncology. Takeda is retiring the Millennium: The Takeda Oncology Company brand, and replacing it with Takeda Oncology to reflect the new global oncology business unit.
Blueprint Health has formed an interdisciplinary group inside and outside of healthcare to develop and assess new healthcare technologies earlier in an effort to reduce risk and to better predict the ROI of solutions earlier, according to a company statement. The Blueprint Health Collective will be totally separate from its New York City-based accelerator.
Steve Silverman resigned this week as the director of the Montgomery County Department of Economic Development.
County spokesman Patrick Lacefield said Silverman, who has served in the role since 2009, left the post to purse a job in the private sector.
Governor Terry McAuliffe on Thursday announced a Virginia Bioscience Initiative, kicking off the effort with a public and private sector roundtable discussion on the commercialization of university bioscience research at the State Capitol. University representatives and bio industry leaders joined the Governor, members of his administration and renowned Massachusetts Institute of Technology Professor Dr. Robert S. Langer for this discussion.
